LGC Clinical Diagnostics has launched our latest NIPT products:
Seraseq® Antepartum and Postpartum T21 Male and 22q11 Male cfDNA reference materials, designed specifically for NIPT of fetal Trisomy 21 (Down Syndrome) and microdeletion 22q11 (DiGeorge Syndrome).
Key Features and Benefits
- Compatible with a broad range of NIPT assay methods, including SNP-based assays and assay where cfDNA size difference is essential
- Patient-like: proprietary method preserving native cfDNA characteristics
- The antepartum cfDNA (containing maternal and fetal cfDNA) can be diluted using the matching postpartum cfDNA (containing only maternal cfDNA) for limit of detection (LoD) studies
- Supplied as purified cfDNA in 0.1X TE buffer for ease of use during library preparation
- Long shelf-life of 4 years and lot-to-lot consistency
ORDERING INFORMATION
Click product for specific product details.
Material # | Product Name | Concentration | Fill Volume | Total Mass |
0720-1100 | New Seraseq Antepartum T21 Male cfDNA | 10 ng/μl | 25 μl | 350-525 ng |
0720-1101 | New Seraseq Postpartum T21 Male cfDNA | 10 ng/μl | 25 μl | 350-525 ng |
0720-1102 | New Seraseq Antepartum 22q11 Male cfDNA | 10 ng/μl | 25 μl | 350-525 ng |
0720-1103 | New Seraseq Postpartum 22q11 Male cfDNA | 10 ng/μl | 25 μl | 350-525 ng |
Questions or Quote Requests
Would you like to speak to a representative?
Email CDx-Sales@lgcgroup.com or call 800-676-1881.
With LGC Clinical Diagnostics, you have access to all of our Quality Measurement Tools product portfolios: